Core Viewpoint - Lupin has reached a settlement with Astellas Pharma to resolve a patent infringement dispute regarding its Mirabegron product, agreeing to pay a total of $90 million, which includes a prepaid option payment of $75 million and a prepaid per-unit license fee for each unit sold until September 2027 [1][5]. Group 1: Settlement Details - The settlement amount totals $90 million, comprising a prepaid option payment of $75 million and additional fees based on product sales [1][5]. - The financial and commercial terms of the settlement remain confidential [2][5]. - The agreement resolves pending litigation with Astellas, allowing Lupin to continue marketing and selling Mirabegron in the U.S., thus eliminating a significant legal hurdle [2][5]. Group 2: Impact on Business Operations - The settlement provides closure to the patent dispute initially disclosed by Lupin in April 2025 [4][5]. - This resolution enhances visibility on the near-term commercial trajectory of the Mirabegron product [4][5].
Lupin clears Mirabegron patent dispute with Astellas in $90 million deal, secures US sales continuity
The Economic Times·2026-02-10 03:14